PDCD1 and melanoma: A phase II clinical trial has enrolled patients to assess the efficacy of the anti-PD-1 mAb, Pembrolizumab, in terms of the function and exhaustion of NK cells in patients with unresectable stage III or IV melanoma (NCT03241927).